1
Clinical Trials associated with Hepatitis B vaccine(Henogen)A Study to Evaluate the Persistence of Anti-HBs Antibodies at Months 12, 24 and 36 in Pre-dialysis or Dialysis Patients Who Have Received a Primary Vaccination Course of Either Henogen's HBV Vaccine, HB-AS02V or GSK Biological's Fendrix™
The current extension study will assess the persistence of anti-HBs antibodies at Months 12, 24 and 36 after primary vaccination with Henogen's HBV vaccine or Fendrix™. This protocol posting deals with the objectives & outcome measures of the extension phase at Months 12, 24 and 36. The objectives & outcome measures of the primary phase are presented in a separate protocol posting (NCT00291941).
100 Clinical Results associated with Hepatitis B vaccine(Henogen)
100 Translational Medicine associated with Hepatitis B vaccine(Henogen)
100 Patents (Medical) associated with Hepatitis B vaccine(Henogen)
100 Deals associated with Hepatitis B vaccine(Henogen)